Chondroitin sulphate, HS and derivatives thereof have also been shown to exert favourable activities against oxidative stress, tau aggregation, the prevention of Aβ associated apoptosis, and possess anti-inflammatory properties [51,52,53,54], demonstrating the potential of non-heparin GAGs as a multi-target drug for the treatment of AD, which would be amenable to oral prophylactic administration. This evidence concerns the gene MAPT and Alzheimer disease.